1. Home
  2. RKTO vs HIND Comparison

RKTO vs HIND Comparison

Compare RKTO & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocket One Inc. Common Stock

RKTO

Rocket One Inc. Common Stock

HOLD

Current Price

$0.53

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Logo Vyome Holdings Inc.

HIND

Vyome Holdings Inc.

N/A

Current Price

$1.80

Market Cap

15.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
RKTO
HIND
Founded
2017
2017
Country
United States
United States
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
15.2M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
RKTO
HIND
Price
$0.53
$1.80
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $8.83
AVG Volume (30 Days)
★ 247.2K
7.8K
Earning Date
11-11-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
29.69
★ 64.86
EPS
N/A
★ N/A
Revenue
N/A
★ $319,714.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$82.65
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 24.43
52 Week Low
$0.48
$1.75
52 Week High
$1.19
$6.56

Technical Indicators

Market Signals
Indicator
RKTO
HIND
Relative Strength Index (RSI) 32.20 35.76
Support Level N/A $1.80
Resistance Level $0.77 $2.31
Average True Range (ATR) 0.05 0.08
MACD -0.01 -0.01
Stochastic Oscillator 17.19 26.47

Price Performance

Historical Comparison
RKTO
HIND

About RKTO Rocket One Inc. Common Stock

Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: